Article

Health Care Cost Growth Among The Privately Insured

Stanford University School of Medicine, California, USA.
Health Affairs (Impact Factor: 4.64). 09/2009; 28(5):1294-304. DOI: 10.1377/hlthaff.28.5.1294
Source: PubMed

ABSTRACT Controlling health care cost growth remains a high priority for policymakers and private decisionmakers, yet little is known about sources of this growth. We examined spending growth among the privately insured between 2001 and 2006, separating the contributions of price changes from those driven by consumption. Most spending growth was driven by outpatient services and pharmaceuticals, with growth in quantities explaining the entire growth in outpatient spending and about three-quarters of growth in spending on prescription drugs. Rising prices played a greater role in growth in spending for brand-name than for generic drugs. These findings can inform efforts to control private- sector spending.

0 Followers
 · 
76 Views
  • Source
    • ") and in other studies that document shifts in utilization (Bundorff et. al. 2009, Chernew and Fendrick 2009). The data are a " convenience " sample and are not designed to provide estimates that are representative for commercially insured patients. The bottom panel of table 1 provides information on the distribution of enrollees. Looking at the distribution of enrollees within a year, our sample has a higher proport"
    [Show abstract] [Hide abstract]
    ABSTRACT: The utilization of health care services has undergone several important shifts in recent years that have implications for the cost of medical care. We empirically document the presence of these shifts for a broad list of medical conditions and assess the implications for price indexes. Following the earlier literature, we compare the growth of two price measures: one that tracks expenditures for the services actually provided to treat conditions and another that holds the mix of those services fixed over time. Using retrospective claims data for a sample of commercially insured patients, we find that, on average, expenditures to treat diseases rose 11% from 2003Q1 to 2005Q4 and would have risen even faster, 18%, had the mix of services remained fixed at the 2003Q1 levels. This suggests that fixed-basket price indexes, as are used in the official statistics, could overstate true price growth significantly.
    Journal of Health Economics 05/2011; 30(3):568-74. DOI:10.1016/j.jhealeco.2011.04.002 · 2.25 Impact Factor
  • Source
    • "Claims datasets such as Pharmetrics and MarketScan have been used in some other studies that explored problems in medical care price indexes (Berndt et al. (2001) and Song et al. (2009)) and in other studies that document shifts in utilization (Bundorff et al. (2009) and Chernew and Fendrick (2009)). Although these indexes are not nationally representative, their advantage is that the large number of observations provides a better representation of spending at the high end of the distribution and the use of administrative records avoids undercount issues typical of household expenditure surveys (Aizcorbe et al. 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, healthcare service utilization has undergone several shifts, having potentially important implications for the cost of medical care.
  • [Show abstract] [Hide abstract]
    ABSTRACT: GH treatment for short children is representative of many frontline issues in health care policy. In this paper, we highlight key policy issues exemplified by GH, focusing on pharmaceutical innovation, insurance coverage and pricing, and physician decisions, and we discuss their implications for endocrinology and GH use.
    The Journal of Clinical Endocrinology and Metabolism 07/2010; 95(7):3149-53. DOI:10.1210/jc.2009-2688 · 6.31 Impact Factor
Show more

Preview

Download
2 Downloads
Available from